Appili Therapeutics, Inc. (APLIF)
0.0068
0.00 (0.00%)
USD |
OTCM |
Oct 26, 16:00
Appili Therapeutics Cash from Investing (Quarterly) : 0.00 for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 0.00 |
| September 30, 2025 | 0.00 |
| June 30, 2025 | 0.00 |
| March 31, 2025 | 0.00 |
| December 31, 2024 | -0.0005M |
| September 30, 2024 | -0.0012M |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.0005M |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | -0.0221M |
| March 31, 2023 | -0.0049M |
| December 31, 2022 | 0.00 |
| September 30, 2022 | -0.0002M |
| June 30, 2022 | 0.0029M |
| Date | Value |
|---|---|
| March 31, 2022 | 0.0006M |
| December 31, 2021 | 0.0163M |
| September 30, 2021 | 0.0071M |
| June 30, 2021 | 4.098M |
| March 31, 2021 | 0.028M |
| December 31, 2020 | 3.665M |
| September 30, 2020 | 7.486M |
| June 30, 2020 | -14.44M |
| March 31, 2020 | 0.00 |
| December 31, 2019 | -0.0001M |
| September 30, 2019 | -0.0006M |
| June 30, 2019 | -0.0001M |
| March 31, 2019 | 0.00 |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | 0.00 |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| InMed Pharmaceuticals, Inc. | 0.00 |
| NervGen Pharma Corp. | -0.0001M |
| Milestone Pharmaceuticals, Inc. | 111.84M |
| Clearmind Medicine, Inc. | -0.7625M |
| Lexaria Bioscience Corp. | -0.0271M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -0.0267M |
| Cash from Financing (Quarterly) | 0.1232M |
| Free Cash Flow | -1.022M |
| Free Cash Flow Per Share (Quarterly) | -0.0002 |
| Free Cash Flow to Equity (Quarterly) | -0.15M |
| Free Cash Flow to Firm (Quarterly) | 0.1561M |
| Free Cash Flow Yield | -116.9% |